Evaluation of Salivary Level of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid

Completed

• Conditions: Oral Lichen Planus
• Interventions: Drug: Triamcinolone Acetonide in orabase

• Registration Number: NCT03871114
• Lead Sponsor: Cairo University

Brief Summary

Thirty patients will be recruited from the outpatient clinic of the faculty of dentistry.fifteen systemically healthy individuals with normal mucosa and fifteen atrophic/erosive oral lichen planus patients. Oral lichen planus patients will be treated with a topical steroid and miR-155 and IL-10 will be assessed in saliva before and after 4 weeks of topical steroids use

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-03-09
• Study First Submitted QC: 2019-03-09
• Study Start: 2019-03-10
• Study First Posted: 2019-03-12
• Primary Completion: 2019-04-10
• Study Completion: 2019-04-25
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-24
• Last Update Posted: 2019-07-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients clinically and histopathologically diagnosed as having atrophic/erosive OLP.
• Patients free from any other oral lesions
• cooperative patients who agrees to take the supplied medications.
• Patients who are systemically healthy

Exclusion Criteria

• Patients suffering from any systemic disease.
• Treatment with any systemic treatment such as systemic steroids, other immunosuppressive drugs or non-steroidal anti-inflammatory drugs at least eight weeks.
• Treatment with any oral topical medications for at least four weeks prior to the study.
• Pregnant and lactating women.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
OLP patients	Triamcinolone Acetonide in orabase	fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks

Primary Outcome Measures

Name	Time	Method
Measurement of salivary levels of miR-155 in OLP before treatment	baseline	assessment of miR-155 in saliva of patients with OLP before treatment
Measurement of salivary levels of IL-10 in OLP before treatment	baseline	assessment of IL-10 in saliva of patients with OLP before treatment

Secondary Outcome Measures

Name	Time	Method
Measurement of salivary levels of miR-155 in OLP after treatment	4 weeks	assessment of miR-155 in saliva of patients with OLP after treatment
Measurement of salivary levels of IL-10 in OLP after treatment	4 weeks	assessment of IL-10 in saliva of patients with OLP after treatment

Trial Locations

Locations (1)

Faculty of Dentistry; 🇪🇬 Cairo, Egypt